
MRD-Guided Decisions May Aid Postremission Treatment Choices in Type of AML
Based on subgroup analyses of over 500 younger patients with intermediate-risk disease, the researchers say measurable residual disease (MRD)-guided decisions may help achieve better outcomes postremission.
Making clinical decisions for patients with intermediate-risk
Based on subgroup analyses of over 500 younger patients (14-60 years) with intermediate-risk disease, the researchers say MRD-guided decisions may be associated with better treatment stratification and improved postremission treatment. They note that prospective multicenter trials are needed to validate these findings.
“It remains a challenge for practitioners to choose the optimal [postremission treatment] for patients with IR-AML because different conclusions have been drawn in previous reports,” explained the researchers, explaining that while some research has indicated that patients with intermediate-risk AML may fare better with allo-SCT, other research has indicated that chemotherapy or auto-SCT may yield better survival.
The study had a few important findings, including:
- Among patients who were MRD negative following induction therapy, those who received chemotherapy and auto-SCT achieved better graft-vs-host-disease–free, relapse-free survival (GRFS) than those who received allo-SCT
- Among patients who has persistent MRD and recurrent MRD, those who received allo-SCT had superior disease-free survival and overall survival (OS) than those who received auto-SCT or chemotherapy
- Among patients who achieved MRD negativity following 2 cycles of chemotherapy, those who received either type of SCT has better disease-free survival and OS compared with those receiving chemotherapy
- Among patients who achieved MRD negativity following 3 cycles of chemotherapy, those receiving allo-SCT had more favorable survival
Based on the findings, the researchers suggest: “[Chemotherapy] and auto-SCT might be preferable for the persistent MRD-negative patients, and allo-SCT should be strongly recommended for the persistent MRD-positive and recurrent MRD-positive patients. Auto-SCT prior to allo-SCT might be recommended for the patients who were MRD negative after 2 cycles of chemotherapy. Allo-SCT might be preferable for the patients who were MRD negative after 3 cycles of chemotherapy.”
Throughout the study period, 146 of the patients relapsed, with a median time from the first course of chemotherapy to relapse of 10.9 months. Patients receiving allo-SCT had the longest time to relapse with a median time to relapse of 13 months compared with a median 10.9 months among patients receiving auto-SCT and a median 9.9 months among patients receiving chemotherapy.
Reference
Yu S, Fan Z, Ma L, et al. Association between measurable disease in patients with intermediate-risk acute myeloid leukemia and first remission, treatment, and outcomes. JAMA Netw Open. 2021;4(7):e2115991.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.